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Abstract
Deep resequencing of functional regions in human genomes is key to identifying potentially causal rare variants for
complex disorders. Here, we present the results from a large-sample resequencing (n= 285 patients) study of candidate
genes coupled with population genetics and statistical methods to identify rare variants associated with Autism Spectrum
Disorder and Schizophrenia. Three genes, MAP1A, GRIN2B, and CACNA1F, were consistently identified by different methods
as having significant excess of rare missense mutations in either one or both disease cohorts. In a broader context, we also
found that the overall site frequency spectrum of variation in these cases is best explained by population models of both
selection and complex demography rather than neutral models or models accounting for complex demography alone.
Mutations in the three disease-associated genes explained much of the difference in the overall site frequency spectrum
among the cases versus controls. This study demonstrates that genes associated with complex disorders can be mapped
using resequencing and analytical methods with sample sizes far smaller than those required by genome-wide association
studies. Additionally, our findings support the hypothesis that rare mutations account for a proportion of the phenotypic
variance of these complex disorders.
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Introduction
Genome-wide interrogation approaches for mapping genes
often are designed to detect the common variants associated with
common phenotypes or disease, generally leaving rare variants
undetected or untested [1–5]. The Rare Allele–Major Effects
(RAME) model postulates that rare (minor allele frequency ,0.01
to 0.05) penetrant variants are key to the genetic etiology of
common disease. Functional mutations that lead to an altered
amino acid are often deleterious and potentially disease causing.
Such mutations are subjected to natural selection, which either
removes these alleles from the population or maintains them at low
frequencies relative to the neutral expectations [3,4,6–9]. Partial
genome or candidate gene resequencing of a large number of
individuals holds the promise of finding both common and rare
variants associated with clinically relevant phenotypes [3,4]. While
a number of studies have mapped common mutations or structural
variants associated with neurological disorders like Autism
Spectrum Disorder (ASD) (e.g. [10]) and Schizophrenia (e.g.
[11]), the RAME model is better suited for modelling diseases that
occur sporadically in families, and for testing whether rare variants
contribute to these disorders.
ASD is a neurodevelopmental disorder characterized by
stereotyped and repetitive behaviours and impairments in social
interactions. Schizophrenia is a chronic psychiatric syndrome
characterized by a profound disruption in cognition, behaviour
and emotion, which begins in adolescence or early adulthood. The
incidence of both ASD and schizophrenia is higher in males than
in females [12,13], which points to an important role of X-
chromosome genes in the two diseases. There is significant clinical
variability among ASD and schizophrenia patients, suggesting that
they are etiologically and genetically heterogeneous. For ASD,
genetics clearly plays an important role in the etiology, as revealed
by twin and familial studies [14–16]. Some susceptibility regions
have been identified through whole genome linkage analyses
[17,18], although they rarely coincide among the different studies
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[19]. Additionally, de novo mutations have been observed [20,21]
and are candidate variants in sporadic cases of either ASD or
schizophrenia, but they explain a small percentage of the
phenotypic variation. Together, these observations suggest that
disruption of numerous genes by rare yet penetrant mutations
could represent a major cause of ASD. Schizophrenia has an
estimated heritability of 80% [22], and it has been recently
associated with common variants at the MHC locus [11,23,24].
There are also several observations suggesting a causal link
between rare mutations and schizophrenia, such as the fact that
patients mostly have no affected close relatives, or the associations
of both paternal age and decreased fertility with the disease [2].
Recent studies also reported de novo copy number variants (CNVs)
in schizophrenia, providing further support for the rare variant
hypothesis in non-familial cases [25–28], as well as an excess of
rare inherited CNVs in familial cases [29].
We hypothesized that capturing genetic variation at low
frequencies (minor allele frequency $0.005) in a large set of
genes expressed in the brain will significantly contribute to our
understanding of the genetic basis of ASD and schizophrenia. If
the RAME model is relevant to these two diseases, the expectation
is an enrichment of rare deleterious mutations among individuals
diagnosed with ASD and schizophrenia. Here, we use population
genetic and other statistical methods to analyze a resequencing
dataset to map genes associated to these two disorders. Using this
approach, we identified candidate genes by testing for genes
harboring an excess of rare missense variants among individuals
affected with ASD and schizophrenia, testing for selection at the
gene level in each disease cohort, and assessing the impact of the
variants found in candidate genes on the study-wide distribution of
missense allele frequencies for each disease cohort.
Results
SNPs Discovered from Deep Resequencing
We resequenced 408 selected brain-expressed genes (Table S1)
in 142 ASD and 143 schizophrenia-affected individuals [21]. The
ASD and schizophrenia cohorts had global ethnicity representa-
tion yet were predominantly European with a large French
Canadian sub-group. It is crucial to exclude ethnic and genetic
outliers when analyzing rare variants because such samples
contain private alleles from other populations. While the results
from the software structure [30] revealed no population structure,
we identified and removed potential ethnic outliers from the
analysis using self reported ethnicity and a principle component
analysis using eignesoft [31] (see Materials and Methods, Figure
S1). The result was a sample of individuals of European ancestry:
ASD (n=102) and schizophrenia (n=138). A total of 285 samples
from the Que´bec Newborn Twin Study (QNTS) [32] were
screened for self reported European ancestry (n=240) and were
used as controls. Thirty-eight (19 autosomal, 19 X-linked) of the
408 brain expressed genes were sequenced in the QNTS controls,
including any gene with de novo mutations previously described in
one of the disease cohorts [21] or with potential protein disrupting
mutations.
We identified a total of 5,396 segregating sites in the disease
cohorts, including 1,111 missense and 11 nonsense variants
(Table 1 and Table 2), from lymphoblastoid cell DNA. As
expected, there was a reduction in nucleotide diversity (p) on the X
chromosome relative to autosomes by a ratio of 0.76 (Table 1),
consistent with neutral expectations for the reduced effective
population size of the X chromosome [33]. The ratio of the male
to female population mutation rate [34] was estimated to be 6.37,
slightly higher but similar to previous estimates of the male
mutation rate being four times the female mutation rate [35]. The
population mutation rate (hW per base pair) for all variants
(including nonsense mutations) was 3.47161024 and 3.4761024
for Schizophrenia and ASD, respectively (Table 1).
Rare Missense Variants Show Increased Predicted
Detrimental Effects
The fact that both ASD and Schizophrenia are highly
heritability and that the common variant associations have been
difficult to replicate support rare variants as an important
component of the genetic etiology of these diseases. If rare
variants are contributing to these diseases, we expect the site
frequency spectrum (SFS) of missense variants to show an excess
of deleterious, low frequency variants in our disease cohorts
relative to either neutral expectations or controls. We analyzed
the proposed detrimental effects of missense variants by
estimating the potential functional effect of the missense variants
observed using the software mapp [36]. Mapp was used to predict
the severity of a missense mutation based on conservation in a
multispecies protein alignment and the physiochemical properties
of the amino acids. Severity scores indicated that 19% of the
missense variants, in 47% of the genes with one or more missense
variants, were likely to adversely affect protein function,
considering a threshold for mapp scores of ten (approximately
P=0.01). Mapp scores are significantly higher for rare versus
common variants (average 7.59 vs. 5.91, Mann-Whitney test
P=1.4561024, Figure S2), and the proportion of variants with
high mapp scores (.10) is also significantly higher in the rare
variants (21%) than in the common variants (11%) (x2 = 8.3,
P=0.0039). These results are consistent with the presence of
deleterious alleles being maintained at low frequency by selection.
However, we did not observe an excess of high mapp scores in
the cases relative to those in the QNTS controls indicating that
rare mutations are likely subject to selection across all populations
and not just cognitive related genes screened among our ASD
and SCZ patients.
Author Summary
It is widely accepted that genetic factors play important
roles in the etiology of neurological diseases. However, the
nature of the underlying genetic variation remains unclear.
Critical questions in the field of human genetics relate to
the frequency and size effects of genetic variants
associated with disease. For instance, the common
disease–common variant model is based on the idea that
sets of common variants explain a significant fraction of
the variance found in common disease phenotypes. On
the other hand, rare variants may have strong effects and
therefore largely contribute to disease phenotypes. Due to
their high penetrance and reduced fitness, such variants
are maintained in the population at low frequencies, thus
limiting their detection in genome-wide association
studies. Here, we use a resequencing approach on a
cohort of 285 Autism Spectrum Disorder and Schizophre-
nia patients and preformed several analyses, enhanced
with population genetic approaches, to identify variants
associated with both diseases. Our results demonstrate an
excess of rare variants in these disease cohorts and identify
genes with negative (deleterious) selection coefficients,
suggesting an accumulation of variants of detrimental
effects. Our results present further evidence for rare
variants explaining a component of the genetic etiology
of autism and schizophrenia.
Gene Mapping Using Population Genetics
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Individual Genes with Excess of Missense and Rare
Missense Variants
We applied three different methods to identify genes harboring
an excess of rare missense variants in the disease cohorts. First, we
identified genes with an excess of missense variants relative to the
number of silent variants observed. For each gene, we used
Fisher’s Exact Test to test the ratio of missense to silent variants
observed within the gene relative to the ratio of missense to silent
variants found in the remaining pooled genes within each cohort,
and separately for X-linked and autosomal loci. The ratio of
missense to silent variants allows us to control for demographic
effects on variation in each cohort and detect genes subject to
natural selection. In both cohorts, the autosomal gene MAP1A
exhibited a significant excess of missense compared to silent
variants (Figure S3, Table S2) (ASD P=0.04, schizophrenia
P=0.03 after Bonferroni correction) and 23 of the 29 missense
variants described in this gene are rare (minor allele frequency
,0.03). MAP1A also exhibits an excess of missense variants when
compared to the total counts of missense and silent variants in the
control cohort (ASD-Control P=0.009, Schizophrenia-Control
P=0.008). To further test the total predicted effect of the missense
variants; for each gene, we summed the mapp scores for all
missense variants within a gene, calculated the ratio of summed
mapp scores to the number of silent variants, and compared these
relative the same ratio in all other genes combined, separately for
autosomal and X-linked loci. While the ratio for MAP1A was not
significant after multiple testing correction, GRIN3A remained
significant, relative to all other genes (P=0.011) for the ASD
cohort.
Second, we tested for an excess of individuals bearing rare
missense variants, using Li and Leal’s collapsing method [37]. We
1) contrasted the ASD and schizophrenia cohorts to each other
(n=277 genes with one or more missense variant in at least one
cohort), 2) compared ASD to the QNTS controls (n=26 genes
with one or more missense variant), and 3) compared the
schizophrenia cohort to the QNTS controls (n=26 genes with
one or more missense variant), and corrected for multiple testing.
For every gene, the number of individuals carrying at least one
rare missense variant, and the number of individuals without rare
missense variants, is compared between two cohorts (see Materials
and Methods). Although the ASD–Schizophrenia comparison
revealed no significant results for any gene, we observed an excess
of individuals with rare missense variants for two genes in the ASD
cohort relative to the controls (GRIN2B and CACNA1F, Bonferroni
adjusted P=0.026, and P=0.031 respectively, Table S3). The
schizophrenia cohort had a significant excess of individuals hosting
rare missense variants at GRIN2B (P=0.041). We repeated this
analysis considering only missense variants predicted to have
detrimental effects on protein function (mapp scores .10). We
found GRIN3A to exhibit an excess of individuals hosting rare
Table 1. Segregating Sites and Diversity in the Disease Cohorts.
Cohort Chromosome Missense Nonsense Silent Intronic UTR Splice Total p* (per bp) hW*(per bp)
ASD
(N=102)
Autosome 574 3 772 1,870 69 1 3,289 4.8461024 3.5861024
X Chrom 124 1 153 508 40 0 826 3.3561024 3.1961024
Total 698 4 925 2,378 109 1 4,115 4.3961024 3.4761024
SCZ
(N=138)
Autosome 614 6 818 1,722 70 0 3,230 4.4561024 3.5461024
X Chrom 164 2 171 536 41 0 914 3.5861024 3.1061024
Total 778 8 989 2,258 111 0 4,144 4.1961024 3.4161024
S2D
(N=240)
Autosome 891 9 1,066 2,169 85 1 4,221 5.2361024 3.4861024
X Chrom 220 2 228 675 50 0 1,175 3.9661024 3.1861024
Total 1,111 11 1,294 2,844 135 1 5,396 4.8461024 3.3961024
QNTS
Control
(N=240)
Autosome 108 0 103 217 5 1 434 4.7261024 6.4161024
X Chrom 18 1 7 14 5 0 45 7.1861025 1.0861024
Total 126 1 110 231 10 1 479 2.7261024 3.7561024
p is mean pair-wise nucleotide diversity across all samples; hW is Watterson’s mutation rate estimator based on the number of segregating sites.
*Estimates were determined for each gene and then averaged across all genes.
doi:10.1371/journal.pgen.1001318.t001
Table 2. Nonsense Mutations in Disease Cohorts.
Chr Positiona Gene
Counts
ASD Counts SCZ
Counts QNTS
Controls
1 20,886,681 KIF17 0 1* 0
6 43,846,749 VEGFA 0 2 0
6 43,856,457 VEGFA 1 0 0
9 103,472,993 GRIN3A 0 1 0
14 71,241,195 SIPA1L1 0 1 NA
14 72,813,605 NUMB 0 1 NA
17 70,362,773 GRIN2C 1 0 0
19 956,224 GRIN3B 1 0 NA
22 49,506,476 SHANK3 0 1* 0
X 43,513,503 MAOB 0 1 NA
X 69,395,157 P2RY4 2 2 6
NA, not analyzed.
aHuman Mar. 2006 (hg18) assembly.
*de novo mutations validated by resequencing parental tissue samples.
doi:10.1371/journal.pgen.1001318.t002
Gene Mapping Using Population Genetics
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detrimental missense variants in the ASD cohort relative to QNTS
controls (P=0.034).
Finally, we used an extension of the McDonald Krietman test,
implemented in mkprf [38], to obtain estimates of c per gene, based
on our observed polymorphisms within humans and substitutions
between humans and an outgroup (Pan troglodytes, see Materials
and Methods). Estimates of the population selection parameter
(cmkprf=2Nes, where Ne is the effective population size and s is the
selection coefficient) will be negative when amino acid replace-
ments are deleterious [39]. Here, we compared the per gene
selection coefficients between cohorts to detect genes enriched for
missense variants in one cohort compared to another. The overall
distribution of cmkprf values among genes was similar between ASD
and schizophrenia (Figure 1). When we contrasted ASD and
schizophrenia cmkprf estimates to those estimated from a Western-
European population [39], we found both the ASD and
schizophrenia cohorts have significantly more negative cmkprf
distributions (Wilcoxon paired test, ASD P=0.0026, schizophre-
nia P=0.0005), while the QNTS controls do not show significant
differences relative to the Western-European dataset (P=0.18).
We also found individual genes that differed significantly among
our cohorts. For example, we observed a significant difference in
Figure 1. Distribution of Individual Locus Selection Coefficients. Posterior mean and 95% CI of cmkprf values by gene in the A) ASD and
Schizophrenia (SCZ) cohorts, gene names colored purple are negatively selected in both cohorts (cmkprf 95% CI,0) and gene names in blue are
positively selected in both cohorts (cmkprf 95% CI.0) B) ASD and Controls (QNTS, and Western European) and C) Schizophrenia and Controls (QNTS,
and Western European).
doi:10.1371/journal.pgen.1001318.g001
Gene Mapping Using Population Genetics
PLoS Genetics | www.plosgenetics.org 4 February 2011 | Volume 7 | Issue 2 | e1001318
cmkprf between the QNTS and ASD cohorts for CACNA1F
(Figure 1B), with the disease cohort having the lower cmkprf
estimate.
The Overall Frequency Spectrum Reveals an Excess of
Rare Deleterious Variants at Autosomal Loci among ASD
and Schizophrenia Individuals
Having identified a number of individual genes with an excess
of deleterious rare alleles, we examined the contribution of these
individual genes to estimates of the population selection param-
eters, cprfreq, across all variants within each cohort. Estimates of
cprfreq will be negative when an excess of low frequency variants are
observed, suggesting an accumulation of deleterious variants [39]
through negative selection. We used the Poisson Random Fields
method implemented in prfreq [40] to infer the demographic and
selection parameters from cohort specific site frequency spectrum
(SFS) and ask 1) whether the SFS of the missense variants showed
evidence of selection relative to the SFS of silent and intronic
variants; 2) if these selection estimates significantly differed
between the disease cohorts and the control cohort; and 3) how
removing the disease associated genes mapped with other
approaches (see above) contribute to the SFS cprfreq estimates.
First, we estimated the demographic parameters for the different
cohorts using the silent and intronic variants discovered among all
autosomal genes. Only genes having at least one or more variant
(265 for disease cohorts, 19 for controls) were included. Next,
while fixing the estimated demographic parameters, the popula-
tion selection parameters (cprfreq) were then estimated from the
missense variants SFS (198 genes with one or more missense
variant in the disease cohorts, 15 such genes for the controls; Table
S4 and Figure S4). In each case, we estimated the likelihood for
that model including the likelihood for a Wright-Fisher neutral
model. The demographic-only model was a significant improve-
ment relative to the neutral model (two times the difference in log
likelihood, P,0.001), and the demographic-with-selection model
was a significant improvement relative to the demographic-only
model (P,0.001)(Table S4). The estimates of cprfreq were more
negative in the two disease cohorts (cprfreqASD=2920, and
cprfreqSCZ=21,100, Table S4 and Figure S4) than for the control
samples (cprfreqcontrol=2740), Specifically, the c
prfreq
SCZ estimate was
significantly more negative than the cprfreqcontrol estimate (P=0.01),
although this pattern was not observed for ASD (P=0.12) (see
Materials and Methods). These observations indicate an excess of
low frequency missense variants in our disease cohorts.
To assess each gene’s contribution to the overall SFS, we
developed an empirical distribution of cprfreq estimates by removing
each gene from the SFS and re-estimating cprfreq. For ASD, when
excluding MAP1A, GRIN3B and RPGRIP1, either individually or
combined, the cprfreq values became more positive (implying less
deleterious effects; cprfreqASD=2880, P[c$2880| empirical distri-
bution] = 0.015 and 2800 respectively) than when estimated for
all variants (cprfreqASD=2920) (Figure 2). These values are also
closer to the cprfreq value estimated in controls (cprfreqcontrol=2740,
see above) and are at the most positive end of the empirical
distribution of cprfreq values (Figure 2A). In the schizophrenia
cohort, we estimated cprfreq values when removing MAP1A and
GRIN3B were cprfreqSCZ=21,020 (P[c$21020 | empirical distri-
bution] = 0.01) and cprfreqSCZ=2980 (P[c$2920 | empirical
distribution] = 0.005), respectively (Figure 2B). When variants in
both the MAP1A and GRIN3B loci were excluded from the SFS,
the estimated cprfreqSCZ increased to 2880, again a value similar to
that observed in controls. These results indicate that the presence
of a few genes, enriched with rare missense variants in the disease
cohorts, is enough to alter the global SFS among all of our
candidate genes. In our case, the overall excess of deleterious
missense variants and the more negative cprfreq estimate in the two
disease cohorts as compared to a neutral cohort is mainly caused
by a very few candidate genes.
Figure 2. Distribution of Population Selection Coefficients Estimated across All Loci. Variation in the population selection parameter
(cprfreq= 2Nes) obtained after excluding every gene with at least one missense variant (198) from the SFS for A) the ASD cohort; * denotes c
prfreq
estimated after removing MAP1A, GRIN3B, and RPGRIP1, and B) the Schizophrenia (SCZ) cohort; * denotes cprfreq estimated after removing MAP1A and
GRIN3B. Genes producing the more important decrease in cprfreq when excluded from the SFS are labeled. Estimates of cprfreq in the control cohort is
also indicated for comparison.
doi:10.1371/journal.pgen.1001318.g002
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Discussion
Using approaches that specifically analyze both the function
and accumulation of rare variants in disease cohorts, we have
found a number of candidate genes associated with ASD and
schizophrenia in two cohorts with sample sizes substantially
smaller than those required for GWA studies. Population genetic
approaches are designed to deal with data where sample sizes are
limited compared to the sizes required in GWA studies. In both
the ASD and schizophrenia cohorts, GRIN2B and MAP1A contain
a statistically significant excess of rare missense variants, while the
excess of rare missense variants in CACNAF1 was restricted to the
ASD cohort. The involvement of a particular gene (e.g. GRIN2B or
MAP1A) in the etiology of both disorders may reflect a critical role
for neurodevelopment processes and suggests a pleiotropic effect
[41]. Population genetic models incorporating demographic and
selection processes, implemented in prfreq, corroborated this result
for MAP1A and CACNA1F, and identified three new candidate
genes: GRIN3B, NOS1, RPGRIP1 (Table 3).
Most of our mapped genes (Table 3, Table S5) have been
previously implicated in neurological disorders or in neurodevel-
opment. MAP1A, a member of the microtubule-associated MAP1
proteins family, is predominantly expressed in adult neurons and is
involved in axon and dendrite development. Among other
interactions, MAP1A participates in the linking of DISC1 to
microtubules [42]. DISC1 is a protein that was described as
related to the pathogenesis of schizophrenia by linkage analysis of
a Scottish family [43,44] and confirmed among Finnish cohorts
[45,46]. The association between schizophrenia and eleven genes
interacting with DISC1 (including MAP1A) was explored in Finish
families, with significant results in three of the candidates but not
for MAP1A [47]. Among calcium channel classes of genes, such as
CACNA1F, we found a significant excess of rare variants and two
segregating inframe indels at CDS position 807 falling in a
glutamic acid-rich coiled domain. CACNA1F has been previously
associated to schizophrenia [48] and mutations have also been
described for other neurological disorders [49]. Finally, two
independent meta-analyses corroborate our findings for a role of
GRIN2B in the etiology of schizophrenia [50,51]. GRIN2B codes a
subunit of the glutamate and N-methyl-D-aspartate (NMDA)
receptor. There exist several NMDA receptors that are construct-
ed with one or more isoforms of the NR1 subunit (GRIN1) in
different combinations with NR2 (GRIN2A, GRIN2B, GRIN2C and
GRIN2D genes) and NR3 subunits (GRIN3A and GRIN3B) [52].
Some studies have suggested a relationship of decreased expression
and abnormalities in NMDA receptors with schizophrenia
[53,54]. Additionally, we observed key results for other NMDA
related genes. GRIN3B had an excess of detrimental variants, two
different analyses revealed significantly higher mapp scores in
GRIN3A in the ASD cohort, while we observed a nonsense
mutation in both GRIN2C and GRIN3A in our cohorts. In the case
of GRIN2B, we also observed a coding indel which results in an
Table 3. Nominal P Values of Identified Candidate Genes Exhibiting Excesses of Rare Variants.
ASD
Missense vs Silenta Collapsing Methodb prfreqc mkprf d
All Missense Rare Missense
GRIN2B 0.016 0.047 0.001* 0.75 27.311 (25.9)
GRIN3B 0.01 0.23 NA 0.015 NA
CACNA1F 0.103 0.028 0.001* NA 20.691** (1.94)
MAP1A 0.0001* 0.0004 NA 0.015 NA
NOS1 0.429 0.536 NA 0.75 1.93 (5.68)
RPGRIP1 0.468 0.162 NA 0.015 2.02 (0.55)
Schizophrenia
Missense vs Silenta Collapsing Methodb prfreqc mkprf d
All Missense Rare Missense
GRIN2B 0.057 0.139 0.001* 0.96 27.6 (25.9)
GRIN3B 0.0029 0.018 NA 0.005 NA
CACNA1F 0.362 0.304 0.14 NA NA
MAP1A 0.0001* 0.0008 NA 0.01 NA
NOS1 0.221 0.142 NA 0.96 22.04** (5.68)
RPGRIP1 0.088 0.298 NA 0.091 0.015 (0.55)
NA, not assessed.
*Significant after Bonferoni Multiple testing.
aSignificant excess of missense and rare missense variants versus silent variants, compared to the rest of genes pooled together in each cohort and separately for X
chromosome and autosomes.
bSignificant excess of individuals with rare missense variants in a given gene. QNTS controls used for the ASD cohort and schizophrenia negative controls used for the
schizophrenia cohort.
cSignificant impact on the overall (autosomes) site frequency spectrum within each disease cohort.
dMean cmkprf of disease cohort and control in parentheses.
**denote mean c significantly more negative in the disease cohort than among QNTS (ASD), SN (SCZ), or Western-European controls. NA are for genes with no available
divergence data.
doi:10.1371/journal.pgen.1001318.t003
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amino acid insertion at cds position 1,353. This collection of rare
and functional changes in the GRIN gene family points to an
important role of NMDA receptors in these neurological disorders.
For some cases in our study, different methods identified
different loci associated with ASD and Schizophrenia. Observing
signficant disease associations for the same genes using all the
methods employed would be ideal, however it is not expected as
each statistical test evaluates a different component of variation
within the data. Furthermore, the ability to use each test varies by
chromosome (X vs. autosomal) and cohort. The Li and Leal
collapsing method [37] evaluates the accumulation of rare
missense variants in genes in cases relative to controls, and is
independent of silent variants. The ratio of missense to silent
mutations is cohort specific and is used to identify genes that have
an excess of missense mutations conditional on the number of
silent mutations, relative to the cohort-wide average. As an
example, a gene can have a minimum of two rare missense
variants and generate a significant result with the collapsing
method, but might not have sufficient power to test the ratio of
rare missense to silent variants.
In contrast, we do expect genes with high missense to silent
variant ratios, to have negative cmkprf estimates, and to contribute
to more negative cprfreq estimates overall. We observed these
patterns for the GRIN2B gene (Table 3) in both diseases which was
supported by a significant collapsing method test result. Like
GRIN2B, CACNA1F also shows concordance among methods
within the ASD cohort; including a nominally significant missense
to silent variant ratio, a significant collapsing method result, and a
negative shift in the cmkprf estimate relative to the control cohort.
Finally, MAP1A has a significant ratio of missense to silent variants
relative to the rest of the genes in both cohorts, and appears to
have a signficant impact on the overall cprfreq estimates for both the
ASD and SCZ cohorts. Due to limited resequencing data in
controls, we were unable to apply the collapsing method to
MAP1A. In conclusion, for GRIN2B, MAP1A, and CACNA1F, we
see concordant results among multiple methods when data
availability allows testing by the different methods.
Previous studies demonstrate that genes associated with
Mendelian disease or cancer have more negative population
selection parameters compared to genes implicated in complex
diseases [55]. This pattern may be explained by a late-onset effect,
or by a potential enrichment of positively selected genes, among
the loci involved in complex disease [55,56]. Another explanation
is that genes which accumulate either rare inherited or de novo
mutations are also more likely to accumulate rare mutations which
individually have either a high impact, as in the case of Mendelian
disorders, or have an intermediate impact in aggregate.
In this paper we hypothesized that rare variants in neurolog-
ically expressed genes are enriched in ASD and schizophrenia
cohorts. Our findings support a rare allele-major effect model as
we have uncovered significant excess of rare variants in our disease
cohorts. It remains an open question if ASD and schizophrenia are
caused by variants found in a reduced set of genes such as DISC1
or NMDA receptor related genes, or in a larger number of genes
associated to the same functional class or pathway/network.
Materials and Methods
Candidate Gene Selection
In total, 408 genes were selected for sequencing: 122 in the X
chromosome and 286 autosomal genes [21] (Table S1) from a
comprehensive list of potential synaptic genes (n = 5,000) based on
published studies and databases [57–62]. X-chromosome synaptic
genes were chosen due to the excess of affected males as compared
to females in individuals affected with schizophrenia [12] and ASD
[13], and since many genes affecting neurodevelopmental brain
diseases happen to be on the X-chromosome [63]. Autosomal
genes implicated in synapse function, including those encoding
glutamate receptors and their interactors were also chosen,
because glutamate signalling is strongly implicated in synapse
function [64]. A total of 38 genes (19 autosomal and 19 X-linked)
with de novo mutations [21] or potentially disrupting protein
mutations in the disease cohorts were chosen for sequencing in the
controls.
Samples
Autism Spectrum Disorder (ASD) subjects. Subjects
diagnosed with autism spectrum disorders and both of their
parents were recruited in clinics specializing in the diagnosis of
Pervasive Developmental Disorders (PDD), rehabilitation centers,
and specialized schools in the Montreal and Quebec regions,
Canada [65]. Subjects with ASD were diagnosed by child
psychiatrists and psychologists specialized in the evaluation of
ASD. All subjects were diagnosed using the Diagnostic and
Statistical Manual (DSM) of Mental Disorders criteria from
patients in the Montreal and surrounding area, and depending on
the recruitment site, either the Autism Diagnostic Interview-
Revised or the Autism Diagnostic Observation Schedule was used.
In addition, the Autism Screening Questionnaire (ASQ) was also
completed for all of our subjects. All samples were French-
Canadian. Furthermore, all proband medical charts were reviewed
by a child psychiatrist expert in PDD to confirm diagnoses.
Exclusion criteria were: (1) an estimatedmental age,18months, (2)
a diagnosis of Rett Syndrome or Childhood Disintegrative Disorder
and (3) evidence of any other psychiatric and neurological
conditions, specifically: birth anoxia, rubella during pregnancy,
fragile-X disorder, encephalitis, phenylketonuria, tuberous sclerosis,
Tourette and West syndromes. Subjects with these conditions were
excluded based on parental interview and chart review. However,
participants with a co-occurring diagnosis of semantic-pragmatic
disorder (due to its large overlap with PDD), attention deficit
hyperactivity disorder (seen in a large number of patients with AD
during development) and idiopathic epilepsy (which is related to the
core syndrome of AD) were eligible for the study.
Schizophrenia subjects. The schizophrenia subjects were
selected from among several large schizophrenia clinical genetic
research centers worldwide. These include: (A) The L.E. Delisi
cohort collected in the USA and Europe [66]. Dr. DeLisi and her
collaborators had identified and collected over 500 families with
schizophrenia or schizoaffective disorder in at least two siblings
over the last two decades. Diagnoses were done using the DSM-
III-R criteria on the basis of structured interviews, review of
medical records from all hospitalizations or other relevant
treatments, and structured information obtained from at least
one reliable family member about each individual. Two
independent diagnoses (one made by Dr. DeLisi) were made for
each individual in the study. In cases of disagreement between the
diagnosing clinicians, a third diagnostician was consulted, and
final diagnoses were made by consensus after discussion. In cases
where there was a sibling diagnosed with schizophrenia, the case
with earlier age of onset and more definite schizophrenia diagnosis
was selected for the initial screening. (B) The R. Joober cohort: Dr.
Joober has collected over 300 schizophrenia families in Montreal in
the past 10 years [67]. The same clinical assessment procedures
have been followed as in (A). In addition, extensive pharmacological
data have been collected in this cohort. (C) The J. Rapoport cohort
(USA): collection includes Childhood Onset Schizophrenia cases
[68]. Individuals in this cohort known to carry the VCFS deletion
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on chromosome 22q11 were excluded. All patients met DSM-IIIR/
DSM-IV criteria for schizophrenia or psychosis not otherwise
specified, had premorbid full-scale IQ scores of 70 or above and
onset of psychotic symptoms by age 12 years. (D) Marie-Odile
Krebs cohort (4 cases) was collected in France: All subjects were
examined according to the standardized Diagnostic Interview for
Genetic Studies (DIGS 3.0) [69]. Family histories of psychiatric
disorders were also collected using the Family Interview for Genetic
Studies (FIGS). All DIGS and FIGS have been reviewed by two or
more psychiatrists for a final consensus diagnosis based on DSM-
IIIR or DSM-IV at each centre. Exclusion criteria for all subjects
included neurologic hard signs (referring to any symptoms or
neurological conditions that can come with psychosis (and not
related to schizophrenia such as Parkinson, Alzheimers, etc.), a
history of head trauma and substance abuse or dependence.
Institutional ethical approval for the study and informed consent
was obtained for all study participants.
From over 500 ASD and 1,000 schizophrenia families, 122
males and 20 females were selected for the ASD cohort, and 95
males and 48 females were selected for the schizophrenia cohort
[21]. The random population cohort (150 males; 135 females) [21]
consist of unrelated individuals collected for the Quebec Newborn
Twin Study (QNTS) [32] where DNA samples were available for
both parents and both twins (either monozygotic or dizygotic),
however only one sibling was chosen randomly for sequencing.
DNA Preparation, Sequencing, and SNP Calling
DNA samples were available for all affected and unaffected
individuals and parents. For certain individuals where blood DNA
was limited, we used DNA isolated from an Epstein-Barr Virus
transformed lymphoblastoid cell line derived from the individual
for the screen. The ASD cell lines samples have been frozen or
regrown a maximum of two times. Genomic DNA was extracted
from peripheral blood lymphocytes for each individual using
Puregene extraction kits (Gentra System, USA). In all cases, rare
variants were confirmed by sequencing both parents and using
blood-derived DNA to rule out variations having arisen during
production or growth of the lymphoblastoid cell line. Parentage
was tested using 17 microsatellite markers. Primers were designed
using the Exon Primer program from the UCSC genome browser.
PCR products were sequenced at the Genome Quebec Innovation
Centre in Montreal, Canada (www.genomequebecplatforms.com/
mcgill/) on a 3730XL DNA Analyzer System. PolyPhred (v6.0)
and Mutation Surveyor (v3.10, Soft Genetics Inc.) were used for
mutation detection analysis. Initial screens were done on cell-line
DNA from samples to conserve blood sample DNA. PolyPhred
(v6.0) scores of 40 or higher were used as the threshold cut-off for
all sequencing reads. When reads did not meet this criterion they
were resequenced. Chromatograms for all rare variants (singletons
or homozygous doubletons) were manually checked. The
sensitivity of singleton detection was previously assessed by
contrasting the heterozygote calls from the sequencing to
heterozygote calls made from Affy SNPChip genotyping, obtain-
ing an estimated false negative rate of heterozygote calls of ,2%
[21]. Variants passing all validation steps were retained for
analysis, resulting in a high confidence dataset.
Population Structure
Structure [30] was used to analyze the degree of population
structure. Analysis of all samples showed no significant population
structure as a large proportion of samples were of the same
ethnicity. Principal Component Analysis (PCA) is more susceptible
to samples with excess of private alleles and revealed genetic
variability between individuals. We removed samples of non-
European ancestry (self-reported ethnicity, ethnic outliers) and
used eigensoft [31] to identify and remove remaining genetic outliers
(defined below). All autosomal variants excluding those with calls
in less than 20 per cohort were used for PCA analysis (4,645
SNPs). We used the linkage disequilibrium correction and
calculated the top 10 principal components (PCs) and removed
individuals with PC projections greater than two standard
deviations or more from the mean, for all significant principal
components, using 10 iterations. Individuals exhibiting excess of
rare variants genome-wide are likely to be genetic outliers and
readily identifiable with PCA and removed, while individuals with
an excess of rare variants in specific genes are retained. To ensure
the PCA outliers were true outliers, we used a one-sided t-test to
assess if the proportion of missense singletons in each PCA outlier
was higher than in PCA retained samples across all autosomal
genes (see Text S1). Structure (admixture model) was used to
reassess levels of population structure within the final sample set
(Figure S1C).
Computational Inferences of Mutation Severity
Mapp was used to predict severity and assign scores to each
missense variant. Orthologous protein sequences were obtained
using the Galaxy Browser (http://main.g2.bx.psu.edu/) and the
UCSC Human Genome Browser (hg18, http://genome.ucsc.edu/
cgi-bin/hgGateway) to generate columns of aligned orthologous
amino acids. Mapp scores and P values were calculated as shown
in Stone and Sidow [36]. Mapp assesses variation observed at each
amino acid position with respect to six physicochemical properties
(hydropathy, polarity, charge, side-chain volume, free energy in
alpha-helical conformation, and free energy in beta-sheet
conformation) after weighting each protein sequence to mitigate
the influence of phylogeny.
Statistical Analysis
Estimating population mutation rates and selection
coefficients. Hclust [70] was used to calculate hW, and p for
each gene in each cohort. Demographic parameters were inferred
from the folded site frequency spectrum (SFS) of silent and intronic
variants using prfreq [40]. Conditioning on the demographic
parameters from the silent and intronic SFS, the likelihood of the
missense SFS was estimated for three models: a Wright-Fisher
neutral population, the demographic model inferred form the
silent and intronic variants, and a demographic with a selection
parameter (cprfreq) model. P values of model improvement were
estimated by comparing the likelihoods, assuming a x2 distribution
of two times the differences in the likelihoods between the models.
To compare the cprfreq values estimated in the ASD and
schizophrenia cohort to the cprfreq values estimated in the control
cohort, we computed the likelihood of the control parameters
estimates in the schizophrenia and ASD cohorts, and compared
these likelihoods to the likelihoods of the ASD and schizophrenia
parameters estimates. We analyzed the effect of each gene with at
least one missense variant (n=198 autosomal genes) on the SFS by
estimating c in all the SFSs resulting from excluding the missense
variants of each individual gene, in each cohort.
Estimating individual gene selection coefficients. The
gene specific selection coefficient, cmkprf, was calculated with the
mkprf program [38] for each cohort (ASD, Schizophrenia, QNTS
Controls). The number of synonymous and nonsynonymous
changes between humans and chimpanzees was obtained from
Bustamante, et al. [39] for 244 genes. Additionally, the European
ancestry samples also reported in Bustamante, et al. [39] were used
as a secondary control data set for this analysis.
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Within-Gene Excess of (Rare) Missense Variants
Fisher’s exact test was used to detect deviations in the missense
to silent variant ratio within genes. For each gene, the ratio of
missense (or rare missense) to silent variants was contrasted to the
same ratio in all remaining genes. This analysis was conducted in
the ASD and schizophrenia cohorts testing autosomal and X-
linked genes separately. We used the Bonferroni correction for
multiple tests (n = 277). Excess of predicted deleterious load within
genes was evaluated by summing the mapp scores for all missense
variants within a gene and testing the ratio of summed mapp
scores to silent variants within the gene relative to all other genes.
This was done separately for autosomes and X-linked genes, and
separately for each disease cohort.
Genes with Excess of Individuals Harboring Rare
Missense Variants
To identify genes with an excess of individuals bearing rare
missense variants, we used Li and Leal’s collapsing method [37].
For ASD vs schizophrenia, ASD vs QNTS, and schizophrenia vs
QNTS controls, the number of individuals with at least one rare
missense mutation and the number of individuals with no rare
missense variants was determined for each cohort, and these
counts made up the cells of the two by two table. We assessed
statistical significance using Fisher’s Exact test and used Bonferro-
ni’s correction for multiple tests (number of genes nASD-SCZ= 277,
nASD – QNTS Controls = 26, nSCZ- QNTS Controls = 26). This analysis
was repeated, considering only missense variants with a mapp
score .10.
Supporting Information
Figure S1 Population Structure of the Disease Cohorts.
Principal component analysis (A, B) and structure analysis of the
disease cohorts (C). In S1A and S1B, each dot denotes a sample’s
position in the top 2 principal components for A) all samples
sequenced and B) samples after excluding ethnic and PCA outlier
filters. Figure C show the structure results for the model of K= 2
populations. Each column corresponds to a sample, red represents
ancestral population 1, and blue represents ancestral population 2.
q is the proportion of the genome from each ancestral population.
Found at: doi:10.1371/journal.pgen.1001318.s001 (0.68 MB EPS)
Figure S2 Mapp values in common versus rare variants. Rare is
defined as minor allele frequency ,0.03.
Found at: doi:10.1371/journal.pgen.1001318.s002 (0.73 MB EPS)
Figure S3 Excess of Missense Variants by Gene. Fisher Exact
Test P of the proportion of A) missense to silent variants and B)
rare missense to all silent variants, at each individual locus
compared to those proportions in the rest of the genes in the ASD
and SCZ cohorts.
Found at: doi:10.1371/journal.pgen.1001318.s003 (0.42 MB EPS)
Figure S4 Observed and Expected Site Frequency Spectrum.
Observed and expected site frequency distributions for the SNPs
the ASD (A), SCZ (B), and controls (C) cohorts. Expected
distributions have been obtained under a neutral model not
including demography, a model with demography, and a model
with demography and selection.
Found at: doi:10.1371/journal.pgen.1001318.s004 (0.28 MB EPS)
Table S1 Genes Resequenced.
Found at: doi:10.1371/journal.pgen.1001318.s005 (0.05 MB
XLS)
Table S2 Counts for Silent to Missense Variant Ratios in
MAP1A.
Found at: doi:10.1371/journal.pgen.1001318.s006 (0.03 MB
DOC)
Table S3 Counts for Collapsing Method for Significant Results.
Found at: doi:10.1371/journal.pgen.1001318.s007 (0.03 MB
DOC)
Table S4 Prfeq Maximum Likelihood Estimates of Demographic
and Selective Models. aAutosomal mutations only. b x2 (P value)
with degrees of freedom being the difference of the number of
estimated parameters. TAU is the time in generations since the non-
stationary dynamics, sclaed by 2*Ncurr. TAU B is the scaled time of
the bottleneck. OMEGA is the ratio of ancestral to current Ne.
Found at: doi:10.1371/journal.pgen.1001318.s008 (0.06 MB
DOC)
Table S5 Variants found in MAP1A, CACNA1F, and
GRIN2B.
Found at: doi:10.1371/journal.pgen.1001318.s009 (0.03 MB
XLS)
Text S1 Population Structure.
Found at: doi:10.1371/journal.pgen.1001318.s010 (0.02 MB
DOC)
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